Biotinylated Human TNF-alpha Protein, epitope tag free, ultra sensitivity (primary amine labeling) (active trimer) (MALS verified)

Source : 

MABSol® Biotinylated Human TNF-alpha, epitope tag free, primary amine labeling (active trimer) (MALS verified) (TNA-H8211) is expressed from human HEK293 cells. It contains AA Val 77 - Leu 233 (Accession # NP_000585.2). It is the biotinylated form of ActiveMax® Human TNF-alpha, Tag Free, low endotoxin (active trimer) (MALS verified) (TNA-H4211).

 

Molecule : TNF-alpha

 

Synonyms : DIF,TNF-alpha,TNFA,TNFSF2,cachexin,cachectin,TNFα

 

Format : Powder

 

Category : MABSol® Biotin Labeled Proteins

 

Accession : NP_000585.2

 

Storage : -20℃

 

Shipping condition : Powder,RT

 

Molecular Weight : 17.4 kDa

 

Characteristics :

The product does NOT contain any epitope tags. The protein has a calculated MW of 17.4 kDa. The protein migrates as 18 kDa on a SDS-PAGE gel under reducing (R) condition.

 

Endotoxin Level : Less than 1.0 EU per μg by the LAL method.

 

Buffer : PBS, pH7.4

 

Description :

Tumor necrosis factor alpha (TNFα) is a cytokine produced primarily by monocytes and macrophages. It is found in synovial cells and macrophages in the tissues.The primary role of TNFα is in the regulation of immune cells. TNFα is able to induce apoptotic cell death, to induce inflammation, and to inhibit tumorigenesis and viral replication. Dysregulation of TNFα production has been implicated in a variety of human diseases, including major depression, Alzheimer's disease and cancer. Recombinant TNFα is used as an immunostimulant under the INN tasonermin. TNFα can be produced ectopically in the setting of malignancy and parallels parathyroid hormone both in causing secondary hypercalcemia and in the cancers with which excessive production is associated.

 

References :

(1) Dowlati Y, Herrmann N, et al., 2010, Biol Psychiatry 67 (5): 446–457.
(2) Swardfager W, Lanctot K, et al., 2010, Biol Psychiatry 68 (10): 930–941.
(3) Locksley RM, Killeen N et al., 2001, Cell 104 (4): 487–501.